Warhound emerges from stealth with $200M to genetically engineer military working dogs, with Anduril gear
Warhound, a startup backed by Colossal Biosciences CEO Ben Lamm and developed in partnership with Anduril (Palmer Luckey), emerged from stealth on 2026-10-22 with $200 million in funding at a $1.2 billion valuation. Investors include In-Q-Tel, Sequoia and 8VC. The company plans to gene-edit and clone working dogs for the U.S. military, law enforcement and emergency response teams. This is business and funding news with no direct cyber threat content.
Detalhes técnicos
- Warhound will take cell lines from Belgian Malinois and German Shepherd dogs, store them in a biobank, and edit genes to improve health, longevity, speed, agility and olfactory capability.
- Viagen, a Colossal-owned company, will handle the cloning. The first batch is expected to be born in early 2027, with service entry targeted within two years.
- Anduril will supply software and hardware add-ons such as sensor-equipped protective vests and goggles that give handlers situational awareness data.
- The company says more than 80% of U.S. military working dogs come from Europe and fewer than half are fit for service.
- Pricing is undetermined. Target buyers are the Department of Defense, military service groups, first responders and police. Lamm says government groups have been briefed.
Linha do tempo
-
Warhound emerges from stealth with $200M to genetically engineer military working dogs, with Anduril gear
ler a análise desta fonte ocultar
Warhound, a startup backed by Colossal Biosciences CEO Ben Lamm and developed in partnership with Anduril (Palmer Luckey), emerged from stealth on 2026-10-22 with $200 million in funding at a $1.2 billion valuation. Investors include In-Q-Tel, Sequoia and 8VC. The company plans to gene-edit and clone working dogs for the U.S. military, law enforcement and emergency response teams. This is business and funding news with no direct cyber threat content.
Technical Details
- Warhound will take cell lines from Belgian Malinois and German Shepherd dogs, store them in a biobank, and edit genes to improve health, longevity, speed, agility and olfactory capability.
- Viagen, a Colossal-owned company, will handle the cloning. The first batch is expected to be born in early 2027, with service entry targeted within two years.
- Anduril will supply software and hardware add-ons such as sensor-equipped protective vests and goggles that give handlers situational awareness data.
- The company says more than 80% of U.S. military working dogs come from Europe and fewer than half are fit for service.
- Pricing is undetermined. Target buyers are the Department of Defense, military service groups, first responders and police. Lamm says government groups have been briefed.